Cardiovascular Risk Associated With Concurrent Proton Pump Inhibitor and Clopidogrel Therapy: Is It Explained by Interaction With CYP2C19 Genotype?

被引：0
|
作者：
Carlquist, John F. [1 ]
Horne, Benjamin D. [1 ]
Huntinghouse, John A. [1 ]
Park, James J. [1 ]
Mower, Chrissa P. [1 ]
Schaefer, Katie [1 ]
Hall, Nathaniel L. [1 ]
Mathews, Katy D. [1 ]
May, Heidi T. [1 ]
Muhlestein, Joseph B. [1 ]
Anderson, Jeffrey L. [1 ]
机构：
[1] Univ Utah, Intermt Med Ctr, Murray, UT USA
来源：
CIRCULATION | 2009年 / 120卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S599 / S599
页数：1
相关论文
共 50 条
  • [31] Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
    Brown, Sherry-Ann
    Pereira, Naveen
    JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (01):
  • [32] EFFECT OF DIFFERENT PROTON PUMP INHIBITORS ON THE ANTI-PLATELET FUNCTION OF CLOPIDOGREL IN RELATION TO CYP2C19 GENOTYPE STATUS.
    Furuta, T.
    Iwaki, T.
    Umemura, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S43 - S43
  • [33] Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype
    Hai-Ling Qiao
    Yu-Rong Hu
    Xin Tian
    Lin-Jing Jia
    Na Gao
    Li-Rong Zhang
    Yu-Zhong Guo
    European Journal of Clinical Pharmacology, 2006, 62 : 107 - 112
  • [34] Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype
    Qiao, HL
    Hu, YR
    Tian, X
    Jia, LJ
    Gao, N
    Zhang, LR
    Guo, YZ
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (02) : 107 - 112
  • [35] Influences of CYP2C19 Polymorphism on Recurrence of Reflux Esophagitis during Proton Pump Inhibitor Maintenance Therapy
    Saitoh, Toshihito
    Otsuka, Hiroko
    Kawasaki, Takahiro
    Endo, Hitoshi
    Iga, Daijirou
    Tomimatsu, Masahiko
    Fukushima, Yasushi
    Katsube, Takao
    Ogawa, Kenji
    Otsuka, Kuniaki
    HEPATO-GASTROENTEROLOGY, 2009, 56 (91-92) : 703 - 706
  • [36] CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Shirai, Naohito
    Ishizaki, Takashi
    PHARMACOGENOMICS, 2007, 8 (09) : 1199 - 1210
  • [37] Incidence of Drug Interaction When Using Proton Pump Inhibitor and Warfarin According to Cytochrome P450 2C19 (CYP2C19) Genotype in Japanese
    Hata, Mitsumasa
    Shiono, Motomi
    Akiyama, Kenji
    Sezai, Akira
    Wakui, Shinji
    Kimura, Haruka
    Sekino, Hisakuni
    THORACIC AND CARDIOVASCULAR SURGEON, 2015, 63 (01): : 45 - 50
  • [38] CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention
    Tunehag, Kayla R.
    Thomas, Cameron D.
    Franchi, Francesco
    Rossi, Joseph S.
    Keeley, Ellen C.
    Anderson, R. David
    Beitelshees, Amber L.
    Duarte, Julio D.
    Gong, Yan
    Kerensky, Richard A.
    Mcdonough, Caitrin W.
    Nguyen, Anh B.
    Ortega-Paz, Luis
    Venkatesh, Sanjay
    Wang, Yehua
    Johnson, Julie A.
    Winterstein, Almut G.
    Stouffer, George A.
    Angiolillo, Dominick J.
    Cavallari, Larisa H.
    Lee, Craig R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (12): : e033791
  • [39] Impact of CYP2C19 genotype in ischaemic stroke patients treated with clopidogrel
    Doney, A.
    Palmer, C.
    Morant, S.
    Flynn, R.
    MacDonald, T.
    INTERNATIONAL JOURNAL OF STROKE, 2015, 10 : 29 - 29
  • [40] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
    Lee, Craig R.
    Luzum, Jasmine A.
    Sangkuhl, Katrin
    Gammal, Roseann S.
    Sabatine, Marc S.
    Stein, Charles Michael
    Kisor, David F.
    Limdi, Nita A.
    Lee, Yee Ming
    Scott, Stuart A.
    Hulot, Jean-Sebastien
    Roden, Dan M.
    Gaedigk, Andrea
    Caudle, Kelly E.
    Klein, Teri E.
    Johnson, Julie A.
    Shuldiner, Alan R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (05) : 959 - 967
12345